OTC Link · Healthcare · Drug Manufacturers - Specialty & Generic
ELITE PHARMS INC
Generic drugmaker posted modest **$0.01 EPS** on $41M revenue with no clear growth catalysts or guidance updates visible. Limited visibility into competitive positioning.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-29 | Q4 2026 | — | 0.01 | — | $40.7M | — | +0.00% | -8.86% | — |
| 2026-02-17 | Q3 2026 | — | 0.01 | — | $31.6M | — | +0.00% | -8.16% | -13.83% |
| 2025-11-14 | Q2 2026 |
| — |
| 0.01 |
| — |
| $36.3M |
| — |
| — |
| — |
| — |
| 2025-08-14 | Q1 2026 | — | -0.01 | — | $40.2M | — | +0.00% | +4.76% | +31.94% |
| 2025-02-13 | Q3 2025 | — | -0.01 | — | $14.4M | — | -3.99% | -9.96% | -12.14% |
| 2024-11-14 | Q2 2025 | — | -0.01 | — | $18.9M | — | +8.46% | +19.32% | -3.61% |
| 2024-08-14 | Q1 2025 | — | 0.00 | — | $18.8M | — | -3.97% | -2.51% | +80.95% |
| 2024-07-01 | Q4 2024 | — | 0.00 | — | $17.9M | — | -6.45% | -5.95% | -6.95% |
Showing last 8 quarters.